Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Standard Oral Care Clear all
Completed Phase 4 Interventional Results available

Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection

NCT00662545
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
Entecavir with continued standard of care antiretroviral therapy, continued standard of care with tenofovir in addition to emtricitabine or lamivudine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 27, 2026, 7:24 PM EDT
Active, not recruiting Phase 1 Interventional

Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma

NCT05236036
View directory record Official record
Conditions
Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy, Temozolomide
Drug · Other · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 27, 2026, 7:24 PM EDT
Terminated Phase 1 Interventional

Distal Radius Steroid

NCT05655130
View directory record Official record
Conditions
Fractures, Bone, Fractures, Closed, Radius Fracture Distal
Interventions
Dexamethasone, Methylprednisolone, Standard of Care
Drug · Other
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 27, 2026, 7:24 PM EDT
Recruiting Phase 2 Interventional

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428
View directory record Official record
Conditions
Carcinoma, Non-small-Cell Lung
Interventions
Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
La Jolla, California • Orange, California • Stanford, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 27, 2026, 7:24 PM EDT
Terminated Not applicable Interventional Results available

Flail Chest - Rib Fixation Study

NCT01147471
View directory record Official record
Conditions
Flail Chest
Interventions
operative rib fixation, operative rib fixation surgery
Device · Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Fresno, California • Charlotte, North Carolina • Winston-Salem, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Sep 27, 2026, 7:24 PM EDT
Terminated Phase 1 Interventional

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

NCT06406400
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
AZD4041, Itraconazole, Buprenorphine, Buprenorphine / Naloxone, Hydromorphone, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 27, 2026, 7:24 PM EDT
Completed Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

NCT03626688
View directory record Official record
Conditions
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions
Ralinepag, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 27, 2026, 7:24 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers

NCT07811297
View directory record Official record
Conditions
Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
Interventions
AL58805, AL3818, Temozolomide (TMZ), CCNU
Drug
Lead sponsor
Advenchen Pharmaceuticals, LLC.
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 27, 2026, 7:24 PM EDT
Completed Not applicable Interventional Results available

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

NCT00970359
View directory record Official record
Conditions
Thyroid Cancer
Interventions
AZD6244
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 27, 2026, 7:24 PM EDT
Recruiting Phase 3 Interventional

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

NCT06992427
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions
Gabapentin, Placebo, Chemotheraphy, Radiation Therapy, Analgesic Agent, Biospecimen Collection, Survey Administration
Drug · Radiation · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
200
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 27, 2026, 7:24 PM EDT
Withdrawn Phase 2 Interventional

Acetazolamide for the Prevention of Post Operative CSF Leak

NCT04351061
View directory record Official record
Conditions
Cerebrospinal Fluid Leak
Interventions
Acetazolamide
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 27, 2026, 7:24 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692
View directory record Official record
Conditions
Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
Ceralasertib, Durvalumab, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
27
States / cities
Mobile, Alabama • Chandler, Arizona • Los Alamitos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 27, 2026, 7:24 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT04553406
View directory record Official record
Conditions
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Interventions
SPR720, Placebo, Open-label Standard of Care
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Sep 27, 2026, 7:24 PM EDT
Recruiting Not applicable Interventional

Nutritional Supplementation in Geriatric Hip Fractures

NCT06773000
View directory record Official record
Conditions
Geriatric Hip Fracture
Interventions
XR™ Recovery Supplement, XR Carbohydrate Loading Supplement
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 27, 2026, 7:24 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

NCT01780844
View directory record Official record
Conditions
Kidney Transplantation
Interventions
ASKP1240, Tacrolimus, Mycophenolate Mofetil (MMF), Basiliximab, Methylprednisone, Prednisone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 27, 2026, 7:24 PM EDT
Terminated Not applicable Interventional Results available

Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)

NCT05093504
View directory record Official record
Conditions
Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
Interventions
Sham comparator, DrugSorb-ATR system
Device
Lead sponsor
CytoSorbents, Inc
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
27
States / cities
Sacramento, California • Denver, Colorado • New Haven, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 27, 2026, 7:24 PM EDT
Not listed Phase 2 Interventional

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)

NCT04874506
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
MBM-02
Drug
Lead sponsor
Matrix Biomed, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 27, 2026, 7:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Fecal Microbiota Transplant for Primary CDI

NCT03795233
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal microbiota transplant G3 capsules, Oral Vancomycin alone
Biological · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 27, 2026, 7:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

NCT02655601
View directory record Official record
Conditions
High Grade Glioma, Astrocytoma, Grade III, Glioblastoma
Interventions
BMX-001, Radiation Therapy, Temozolomide
Drug · Radiation
Lead sponsor
BioMimetix JV, LLC
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 27, 2026, 7:24 PM EDT
Terminated Phase 1 Interventional Results available

Oral Rehydration Therapy in Burn Patients

NCT02124265
View directory record Official record
Conditions
Burn Any Degree Involving 20-29 Percent of Body Surface, Burn Any Degree Involving 30-39 Percent of Body Surface, Burn Any Degree Involving 40-49 Percent of Body Surface, Burn Any Degree Involving 50-59 Percent of Body Surface, Burn Any Degree Involving 60-65 Percent of Body Surface, Fluid Resuscitation
Interventions
CeraLyte 90
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Sep 27, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

NCT03193853
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Tak-228 & Tak-117, Cisplatin & Nab Paclitaxel
Drug
Lead sponsor
Joyce O'Shaughnessy
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 27, 2026, 7:24 PM EDT
Active, not recruiting Phase 1 Interventional

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT06824701
View directory record Official record
Conditions
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Interventions
Zanubrutinib, Rituximab, Obinutuzumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 27, 2026, 7:24 PM EDT
Recruiting Phase 1 Interventional

Pharmacologic Augmentation of TMS for Depression With D-serine

NCT06876129
View directory record Official record
Conditions
Depression
Interventions
TMS, D-serine, Placebo
Device · Drug · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 27, 2026, 7:24 PM EDT
Completed Phase 3 Interventional Results available

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

NCT01607957
View directory record Official record
Conditions
Colorectal Cancer
Interventions
TAS-102, Placebo
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
23
States / cities
Glendale, Arizona • Fresno, California • Gilroy, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 27, 2026, 7:24 PM EDT